Skip to main content
Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0040
-0.0060 (-60.00%)
Apr 28, 2026, 4:00 PM EST

Adaptimmune Therapeutics Revenue

Adaptimmune Therapeutics had revenue of $13.68M in the quarter ending June 30, 2025, a decrease of -89.33%. This brings the company's revenue in the last twelve months to $65.09M, down -53.99% year-over-year. In the year 2024, Adaptimmune Therapeutics had annual revenue of $178.03M with 195.34% growth.

Revenue (ttm)
65.09M
Revenue Growth
-53.99%
P/S Ratio
0.01
Revenue / Employee
128.63K
Employees
506
Market Cap
927.68K

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024178.03M117.75M195.34%
Dec 31, 202360.28M33.13M122.05%
Dec 31, 202227.15M21.00M341.50%
Dec 31, 20216.15M2.19M55.36%
Dec 31, 20203.96M2.84M252.76%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Lyra Therapeutics 398.00K
Enzolytics 46.59K
International Stem Cell 9.10M
LakeShore Biopharma 84.75M
Evofem Biosciences 20.18M
Revenue Rankings

Adaptimmune Therapeutics News

More News